Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
about
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and reportPSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusProstate-specific membrane antigen as a target for cancer imaging and therapyReal-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate CancerPET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesTarget Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular ImagingBiomarkers in preclinical cancer imaging.Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.AEG-1 promoter-mediated imaging of prostate cancer.Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer MeetingMolecular-genetic imaging of cancer.Imaging active urokinase plasminogen activator in prostate cancer.Development of targeted near-infrared imaging agents for prostate cancerSelection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerA Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical ApplicationAuger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane AntigenImaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimatesMolecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Translational Molecular Imaging of Prostate Cancer.Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.Molecular imaging of urogenital diseases.Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cellsPreclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring.(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.PET imaging in prostate cancer: focus on prostate-specific membrane antigenThe prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.Nuclear imaging of renal tumours: a step towards improved risk stratification.Next revolution in molecular theranostics: personalized medicine for urologic cancers.Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo.
P2860
Q26747480-6C95AC7D-622B-46C7-9591-A02143993233Q26774920-FF463C48-9AF2-4D8A-ADF1-E039E153B2C6Q26799439-67A339B2-F294-49DD-901B-A7839DBA4451Q27346788-A235D3BE-8E01-440A-8CE1-07D9CFF72AA5Q27705945-951EAE32-7862-48D8-90D0-0A5C05282218Q28067404-01203606-4D4D-4073-BDE1-5C3058E4B2B0Q28074669-679431A0-A3AF-4EC9-961D-E85D69A5B99FQ30416864-78819809-9270-4B79-A1B2-954977F63644Q33711641-D30B7BB1-65EB-41E5-BC54-157E4AC52DFEQ33914844-C33F8967-B6E1-43A5-BA6C-F5CC9AA36EADQ34038524-1EC840D3-9B5B-4CC5-BBCC-2C5B9FA0570DQ34139498-5A0A23C5-F312-4180-BB0F-E3B232406A55Q34522714-3ABE9DB6-48AF-4A9D-A309-122C2BA13EE1Q34617627-FBE94A7A-6386-4CEA-B437-0123D87447B6Q35116121-DD5A26B3-1C9B-4CDA-B9D0-8E5722DB777DQ35251858-1D4CBB8D-CD2F-43A3-BAC5-F2F2DAD8D2DCQ35754837-851CCDE3-A0F4-4D28-8761-C95E688803DBQ35902274-FEBF1DEB-4C1C-4B22-9372-36E26823AD40Q35938051-5EAA39EC-A34C-4AA8-874B-98E0B6B251C1Q35942615-4D4199B4-22E9-4BF0-904D-9D9BA3EA1488Q36252485-0ACC4DB1-5C88-4428-890E-D3922D1EE630Q36545270-0193FB36-28C1-470B-A2E6-D009159B98BBQ36867784-01D3184A-D856-43FF-9CDB-41BBEEC4E3B7Q36928870-7C3DBB15-6AB6-409F-8288-A7A0D0D6FC51Q37092020-873BBE31-EFF2-4B7E-8E58-895753631EE1Q37244969-A20779D7-B6D2-47FF-B7DC-1A83522258EDQ37390674-A331732E-F68B-40EE-AE39-526D476FA01CQ37550399-73A216B8-2640-4021-8A2C-A84F2606A1BFQ37591940-1055B012-684A-4352-A5DD-F11551A05D03Q37623394-3FAC729E-42F1-45E8-ABD9-63DF21FF5B25Q37662669-BFA9E90D-2575-4394-83B3-80D190BFC440Q37662752-347A9D6F-9EA6-443D-B8E5-6CCA7F8E4DDEQ37714485-9698F8F6-998E-40E5-86A1-241C60710C06Q37722429-700E1815-EFAC-480E-8F91-4CFFB79D2A5AQ38099369-38161C35-A890-4EE3-B6DE-C60E5B483582Q38169828-27F1CAA3-2BF0-4B93-9E4F-4CB464632BC8Q38360681-62DD1616-B634-4CFA-AB14-BC5188DADEB9Q38521920-C5D6AC10-DA38-4584-A018-795CC4134C5BQ38559336-813E2FD5-DC5D-465C-B531-B5AB84AF1817Q38604581-271C2220-1E0D-4925-81AC-498952D53E05
P2860
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biodistribution, tumor detecti ...... th metastatic prostate cancer.
@en
Biodistribution, tumor detecti ...... th metastatic prostate cancer.
@nl
type
label
Biodistribution, tumor detecti ...... th metastatic prostate cancer.
@en
Biodistribution, tumor detecti ...... th metastatic prostate cancer.
@nl
prefLabel
Biodistribution, tumor detecti ...... th metastatic prostate cancer.
@en
Biodistribution, tumor detecti ...... th metastatic prostate cancer.
@nl
P2093
P2860
P1476
Biodistribution, tumor detecti ...... th metastatic prostate cancer.
@en
P2093
Akimosa Jeffrey-Kwanisai
Alan P Kozikowski
Barbara S Slusher
Camilo Rojas
Christopher J Endres
Daniel P Holt
Mario A Eisenberger
Martin G Pomper
Martin Lodge
Michael A Carducci
P2860
P304
P356
10.2967/JNUMED.112.104661
P407
P577
2012-12-01T00:00:00Z